You are here

Gilead Announces Heart Problems With Sovaldi and Harvoni in Nonapproved Combinations

Warning could limit drugs’ use

Gilead Sciences has announced that nine patients taking its hepatitis C drug Sovaldi (sofosbuvir) or Harvoni (ledipasvir/sofosbuvir) along with amiodarone developed abnormally slow heartbeats, and that one died of cardiac arrest. Three required the insertion of a pacemaker.

Gilead said in a drug warning e-mailed to health-care providers on March 20 that six cases of symptomatic bradycardia occurred within the first 24 hours of treatment and that the remaining three occurred within the first 2 to 12 days. The patients were all taking amiodarone, with three also using Harvoni, five receiving Sovaldi with daclatasvir (Bristol-Myers Squibb), and one receiving Sovaldi with simeprevir (Olysio, Johnson & Johnson). Gilead said that these combinations aren’t recommended, and that it will update its product labeling accordingly.

The warning might limit the use of Sovaldi and Harvoni, which have transformed how hepatitis C virus infection is treated, with most patients being cured after 12 weeks of treatment. The drugs also have drawn criticism for their cost of more than $1,000 a day before discounts, or as much as $94,500 for a full course of treatment.

Harvoni generated $2.11 billion in sales in the fourth quarter of 2014, and Sovaldi brought in $1.73 billion, together contributing more than half of Gilead’s total revenue of $7.31 billion, according to the Bloomberg business website. The drugs’ hefty profit margins helped boost fourth-quarter net income more than fourfold to $3.49 billion.

Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), a competing treatment introduced late last year by AbbVie, has put pressure on Gilead’s prices.

Source: Bloomberg Business; March 23, 2015.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs